Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis.

Ventriglia J, Petrillo A, Huerta Alváro M, Laterza MM, Savastano B, Gambardella V, Tirino G, Pompella L, Diana A, Iovino F, Troiani T, Martinelli E, Morgillo F, Orditura M, Cervantes A, Ciardiello F, De Vita F.

Gastroenterol Res Pract. 2018 Jun 10;2018:2373868. doi: 10.1155/2018/2373868. eCollection 2018.

2.

Systemic-inflammation-based score can predict prognosis in metastatic gastric cancer patients before first-line chemotherapy.

Petrillo A, Laterza MM, Tirino G, Pompella L, Ventriglia J, Pappalardo A, Famiglietti V, Martinelli E, Ciardiello F, Orditura M, Galizia G, De Vita F.

Future Oncol. 2018 Jul 3. doi: 10.2217/fon-2018-0167. [Epub ahead of print]

PMID:
29969285
3.

Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis.

Brunetti O, Aprile G, Marchetti P, Vasile E, Casadei Gardini A, Scartozzi M, Barni S, Delfanti S, De Vita F, Di Costanzo F, Milella M, Cella CA, Berardi R, Cataldo I, Scarpa A, Basile D, Mazzuca F, Graziano G, Argentiero A, Santini D, Reni M, Cascinu S, Silvestris N.

Pancreas. 2018 Jul;47(6):759-771. doi: 10.1097/MPA.0000000000001063.

PMID:
29771769
4.

Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study.

Di Bartolomeo M, Niger M, Tirino G, Petrillo A, Berenato R, Laterza MM, Pietrantonio F, Morano F, Antista M, Lonardi S, Fornaro L, Tamberi S, Giommoni E, Zaniboni A, Rimassa L, Tomasello G, Sava T, Spada M, Latiano T, Bittoni A, Bertolini A, Proserpio I, Bencardino KB, Graziano F, Beretta G, Galdy S, Ventriglia J, Scagnoli S, Spallanzani A, Longarini R, De Vita F.

Target Oncol. 2018 Apr;13(2):227-234. doi: 10.1007/s11523-018-0562-5.

PMID:
29582224
5.

Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance.

Tehfe M, Tabchi S, Laterza MM, De Vita F.

Future Oncol. 2018 Feb;14(3):223-228. doi: 10.2217/fon-2017-0434. Epub 2018 Jan 10.

PMID:
29318901
6.

Plantar Kaposi Sarcoma Revealed by Antisynthetase Syndrome.

Sellitto A, Adinolfi LE, Romano C, Iovino F, Auriemma PP, Russo D, de Vita F.

J Clin Rheumatol. 2017 Dec 12. doi: 10.1097/RHU.0000000000000650. [Epub ahead of print] No abstract available.

PMID:
29239932
7.

Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment.

Martinelli E, Sforza V, Cardone C, Capasso A, Nappi A, Martini G, Napolitano S, Rachiglio AM, Normanno N, Cappabianca S, Reginelli A, Bisceglie MD, Latiano TP, Maiello E, Orditura M, De Vita F, Morgillo F, Ciardiello F, Troiani T.

ESMO Open. 2017 Jul 29;2(3):e000177. doi: 10.1136/esmoopen-2017-000177. eCollection 2017.

8.

Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.

Pietrantonio F, Fucà G, Morano F, Gloghini A, Corso S, Aprile G, Perrone F, De Vita F, Tamborini E, Tomasello G, Gualeni AV, Ongaro E, Busico A, Giommoni E, Volpi CC, Laterza MM, Corallo S, Prisciandaro M, Antista M, Pellegrinelli A, Castagnoli L, Pupa SM, Pruneri G, de Braud F, Giordano S, Cremolini C, Di Bartolomeo M.

Clin Cancer Res. 2018 Mar 1;24(5):1082-1089. doi: 10.1158/1078-0432.CCR-17-2781. Epub 2017 Dec 5.

PMID:
29208673
9.

Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells.

Morgillo F, Della Corte CM, Diana A, Mauro CD, Ciaramella V, Barra G, Belli V, Franzese E, Bianco R, Maiello E, de Vita F, Ciardiello F, Orditura M.

Oncotarget. 2017 Aug 22;8(44):76479-76491. doi: 10.18632/oncotarget.20385. eCollection 2017 Sep 29.

10.

Efficacy of a triplet and doublet-based chemotherapy as first-line therapy in patients with HER2-negative metastatic gastric cancer: a retrospective analysis from the clinical practice.

Laterza MM, Pompella L, Petrillo A, Tirino G, Pappalardo A, Orditura M, Troiani T, Ciardiello F, Di Martino N, De Vita F.

Med Oncol. 2017 Oct 17;34(11):186. doi: 10.1007/s12032-017-1046-7.

PMID:
29043514
11.

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.

Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, Tejani MA, Udrea AA, Tehfe M, De Vita F, Turkington C, Tang R, Ang A, Zhang Y, Hoang T, Sidhu R, Cunningham D.

Lancet Oncol. 2017 Nov;18(11):1467-1482. doi: 10.1016/S1470-2045(17)30566-1. Epub 2017 Sep 25.

PMID:
28958504
12.

Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial.

Martinelli E, Cardone C, Troiani T, Normanno N, Pisconti S, Sforza V, Bordonaro AR, Rachiglio AM, Lambiase M, Latiano TP, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E, Ciardiello F.

ESMO Open. 2017 Feb 20;1(6):e000086. doi: 10.1136/esmoopen-2016-000086. eCollection 2016.

13.

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma.

Rossetti S, D'Aniello C, Iovane G, Scagliarini S, Laterza MM, De Vita F, Savastano C, Cartenì G, Porricelli MA, Berretta M, Pisconti S, Facchini G, Cavaliere C.

Front Pharmacol. 2017 Jul 20;8:484. doi: 10.3389/fphar.2017.00484. eCollection 2017.

14.

Thyroid Surgery: To Drain or Not to Drain, That Is the Problem - A Randomized Clinical Trial.

Schietroma M, Pessia B, Bianchi Z, De Vita F, Carlei F, Guadagni S, Amicucci G, Clementi M.

ORL J Otorhinolaryngol Relat Spec. 2017;79(4):202-211. doi: 10.1159/000464137. Epub 2017 Jul 15.

PMID:
28715809
15.

Mitochondrial AKAP1 supports mTOR pathway and tumor growth.

Rinaldi L, Sepe M, Delle Donne R, Conte K, Arcella A, Borzacchiello D, Amente S, De Vita F, Porpora M, Garbi C, Oliva MA, Procaccini C, Faicchia D, Matarese G, Zito Marino F, Rocco G, Pignatiello S, Franco R, Insabato L, Majello B, Feliciello A.

Cell Death Dis. 2017 Jun 1;8(6):e2842. doi: 10.1038/cddis.2017.241.

16.

[Gastric carcinoma: an evolutionary scenario.]

Gelsomino F, Spallanzani A, De Vita F, Di Bartolomeo M, Gavazzi C, Rimassa L, Cascinu S.

Recenti Prog Med. 2017 Mar;108(3):120-127. doi: 10.1701/2656.27234. Italian.

PMID:
28398405
17.

Comparison of the current AJCC-TNM numeric-based with a new anatomical location-based lymph node staging system for gastric cancer: A western experience.

Galizia G, Lieto E, Auricchio A, Cardella F, Mabilia A, Diana A, Castellano P, De Vita F, Orditura M.

PLoS One. 2017 Apr 5;12(4):e0173619. doi: 10.1371/journal.pone.0173619. eCollection 2017.

18.

Complete response to capecitabine in a frail, elderly patient with metastatic colorectal cancer: A case report.

Fasano M, Fabozzi A, Giordano G, Venturini F, Aurilio G, Cantile F, Fabozzi T, Ricci V, Santabarbara G, Morgillo F, Ciardiello F, De Vita F.

Oncol Lett. 2017 Feb;13(2):979-983. doi: 10.3892/ol.2016.5523. Epub 2016 Dec 20.

19.

Predictive biomarkers along gastric cancer pathogenetic pathways.

Panarese I, De Vita F, Ronchi A, Romano M, Alfano R, Di Martino N, Zito Marino F, Ferraraccio F, Franco R.

Expert Rev Anticancer Ther. 2017 May;17(5):417-425. doi: 10.1080/14737140.2017.1301207. Epub 2017 Mar 15. Review.

PMID:
28277834
20.

Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review.

Fasano M, Della Corte CM, Vicidomini G, Scotti V, Rambaldi PF, Fiorelli A, Accardo M, De Vita F, Santini M, Ciardiello F, Morgillo F.

Oncol Lett. 2016 Dec;12(6):4505-4509. doi: 10.3892/ol.2016.5279. Epub 2016 Oct 18.

21.

Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis.

Orditura M, Galizia G, Diana A, Saccone C, Cobellis L, Ventriglia J, Iovino F, Romano C, Morgillo F, Mosca L, Diadema MR, Lieto E, Procaccini E, De Vita F, Ciardiello F.

ESMO Open. 2016 Mar 7;1(2):e000038. eCollection 2016.

22.

Pancreatic stump closure after pancreatoduodenectomy in elderly patients: a retrospective clinical study.

Mauriello C, Polistena A, Gambardella C, Tartaglia E, Orditura M, De Vita F, Santini L, Avenia N, Conzo G.

Aging Clin Exp Res. 2017 Feb;29(Suppl 1):35-40. doi: 10.1007/s40520-016-0657-8. Epub 2016 Nov 11.

23.

Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study.

D'Aniello C, Vitale MG, Farnesi A, Calvetti L, Laterza MM, Cavaliere C, Della Pepa C, Conteduca V, Crispo A, De Vita F, Grillone F, Ricevuto E, De Tursi M, De Vivo R, Di Napoli M, Cecere SC, Iovane G, Amore A, Piscitelli R, Quarto G, Pisconti S, Ciliberto G, Maiolino P, Muto P, Perdonà S, Berretta M, Naglieri E, Galli L, Cartenì G, De Giorgi U, Pignata S, Facchini G, Rossetti S.

Front Pharmacol. 2016 Sep 28;7:331. eCollection 2016.

24.

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice.

De Vita F, Ventriglia J, Febbraro A, Laterza MM, Fabozzi A, Savastano B, Petrillo A, Diana A, Giordano G, Troiani T, Conzo G, Galizia G, Ciardiello F, Orditura M.

BMC Cancer. 2016 Sep 2;16(1):709. doi: 10.1186/s12885-016-2671-9.

25.

HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.

Pietrantonio F, Caporale M, Morano F, Scartozzi M, Gloghini A, De Vita F, Giommoni E, Fornaro L, Aprile G, Melisi D, Berenato R, Mennitto A, Volpi CC, Laterza MM, Pusceddu V, Antonuzzo L, Vasile E, Ongaro E, Simionato F, de Braud F, Torri V, Di Bartolomeo M.

Int J Cancer. 2016 Dec 15;139(12):2859-2864. doi: 10.1002/ijc.30408. Epub 2016 Sep 16.

26.

Quality of wound dressings: a first step in establishing shared criteria and objective procedures to evaluate their performance.

Mennini N, Greco A, Bellingeri A, De Vita F, Petrella F.

J Wound Care. 2016 Aug;25(8):428-37. doi: 10.12968/jowc.2016.25.8.428.

PMID:
27523654
27.

Instrumental and Non-Instrumental Evaluation of 4-Meter Walking Speed in Older Individuals.

Maggio M, Ceda GP, Ticinesi A, De Vita F, Gelmini G, Costantino C, Meschi T, Kressig RW, Cesari M, Fabi M, Lauretani F.

PLoS One. 2016 Apr 14;11(4):e0153583. doi: 10.1371/journal.pone.0153583. eCollection 2016.

28.

Malignant transformation in non-recurrent peritoneal cystic mesothelioma Our experience and review of the literature.

Santangelo G, Accardo M, De Vita F, Del Giudice S, Gallucci F, Fabozzi A, De Falco M.

Ann Ital Chir. 2016 Jan 29;87(ePub). pii: S2239253X16023343.

PMID:
27031307
29.

Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.

Ciardiello F, Normanno N, Martinelli E, Troiani T, Pisconti S, Cardone C, Nappi A, Bordonaro AR, Rachiglio M, Lambiase M, Latiano TP, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E; CAPRI-GOIM Investigators; CAPRI-GOIM investigators.

Ann Oncol. 2016 Jun;27(6):1055-61. doi: 10.1093/annonc/mdw136. Epub 2016 Mar 21.

PMID:
27002107
30.

The Role of the Multiple Hormonal Dysregulation in the Onset of "Anemia of Aging": Focus on Testosterone, IGF-1, and Thyroid Hormones.

Maggio M, De Vita F, Fisichella A, Lauretani F, Ticinesi A, Ceresini G, Cappola A, Ferrucci L, Ceda GP.

Int J Endocrinol. 2015;2015:292574. doi: 10.1155/2015/292574. Epub 2015 Dec 8. Review.

31.

Pancreatic neuroendocrine tumors: Nosography, management and treatment.

Orditura M, Petrillo A, Ventriglia J, Diana A, Laterza MM, Fabozzi A, Savastano B, Franzese E, Conzo G, Santini L, Ciardiello F, De Vita F.

Int J Surg. 2016 Apr;28 Suppl 1:S156-62. doi: 10.1016/j.ijsu.2015.12.052. Epub 2015 Dec 18. Review.

32.

Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.

Della Corte CM, Ciaramella V, Di Mauro C, Castellone MD, Papaccio F, Fasano M, Sasso FC, Martinelli E, Troiani T, De Vita F, Orditura M, Bianco R, Ciardiello F, Morgillo F.

Oncotarget. 2016 Jan 26;7(4):4265-78. doi: 10.18632/oncotarget.6559.

33.

Relationship between Carotenoids, Retinol, and Estradiol Levels in Older Women.

Maggio M, de Vita F, Lauretani F, Bandinelli S, Semba RD, Bartali B, Cherubini A, Cappola AR, Ceda GP, Ferrucci L.

Nutrients. 2015 Aug 5;7(8):6506-19. doi: 10.3390/nu7085296.

34.

INSULIN-LIKE GROWTH FACTOR-1 AND ANEMIA IN OLDER SUBJECTS: THE INCHIANTI STUDY.

De Vita F, Maggio M, Lauretani F, Crucitti L, Bandinelli S, Mammarella F, Landi F, Ferrucci L, Ceda GP.

Endocr Pract. 2015 Nov;21(11):1211-8. doi: 10.4158/EP14100.OR. Epub 2015 Jul 27.

35.

Conservative management and parenchyma-sparing resections of pancreatic neuroendocrine tumors: Literature review.

Mauriello C, Napolitano S, Gambardella C, Candela G, De Vita F, Orditura M, Sciascia V, Tartaglia E, Lanza M, Santini L, Conzo G.

Int J Surg. 2015 Sep;21 Suppl 1:S10-4. doi: 10.1016/j.ijsu.2015.04.089. Epub 2015 Jun 26. Review.

36.

Pancreatic fistula following pancreatoduodenectomy. Evaluation of different surgical approaches in the management of pancreatic stump. Literature review.

Conzo G, Gambardella C, Tartaglia E, Sciascia V, Mauriello C, Napolitano S, Orditura M, De Vita F, Santini L.

Int J Surg. 2015 Sep;21 Suppl 1:S4-9. doi: 10.1016/j.ijsu.2015.04.088. Epub 2015 Jun 26. Review.

37.

Mutant AKT1-E17K is oncogenic in lung epithelial cells.

De Marco C, Malanga D, Rinaldo N, De Vita F, Scrima M, Lovisa S, Fabris L, Carriero MV, Franco R, Rizzuto A, Baldassarre G, Viglietto G.

Oncotarget. 2015 Nov 24;6(37):39634-50. doi: 10.18632/oncotarget.4022.

38.

c-Met targeting in advanced gastric cancer: An open challenge.

Marano L, Chiari R, Fabozzi A, De Vita F, Boccardi V, Roviello G, Petrioli R, Marrelli D, Roviello F, Patriti A.

Cancer Lett. 2015 Aug 28;365(1):30-6. doi: 10.1016/j.canlet.2015.05.028. Epub 2015 Jun 3. Review.

PMID:
26049023
39.

Treatment of esophagogastric junction carcinoma: an unsolved debate.

Orditura M, Galizia G, Lieto E, De Vita F, Ciardiello F.

World J Gastroenterol. 2015 Apr 21;21(15):4427-31. doi: 10.3748/wjg.v21.i15.4427. Review.

40.

Neutrophil to lymphocyte ratio is a strong predictor of tumor recurrence in early colon cancers: A propensity score-matched analysis.

Galizia G, Lieto E, Zamboli A, De Vita F, Castellano P, Romano C, Auricchio A, Cardella F, De Stefano L, Orditura M.

Surgery. 2015 Jul;158(1):112-20. doi: 10.1016/j.surg.2015.02.006. Epub 2015 Mar 25.

PMID:
25818659
41.

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis.

Federico A, Orditura M, Cotticelli G, DE Sio I, Romano M, Gravina AG, Dallio M, Fabozzi A, Ciardiello F, Loguercio C, DE Vita F.

Oncol Lett. 2015 Apr;9(4):1628-1632. Epub 2015 Feb 12.

42.

MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib.

Stiuso P, Potenza N, Lombardi A, Ferrandino I, Monaco A, Zappavigna S, Vanacore D, Mosca N, Castiello F, Porto S, Addeo R, Prete SD, De Vita F, Russo A, Caraglia M.

Mol Ther Nucleic Acids. 2015 Mar 17;4:e233. doi: 10.1038/mtna.2015.8.

43.

Seasonal DXA-measured body composition changes in professional male soccer players.

Milanese C, Cavedon V, Corradini G, De Vita F, Zancanaro C.

J Sports Sci. 2015;33(12):1219-28. doi: 10.1080/02640414.2015.1022573. Epub 2015 Mar 16.

PMID:
25773172
44.

Vertebral carcinomatosis eleven years after advanced gastric cancer resection: A case report.

Iovino F, Orditura M, Auriemma PP, Ciorra FR, Giordano G, Orabona C, Bara F, Sergio R, Savastano B, Fabozzi A, Laterza MM, Ventriglia J, Petrillo A, Della Corte CM, DE Vita F.

Oncol Lett. 2015 Mar;9(3):1403-1405. Epub 2014 Dec 23.

45.

CD26-positive/CD326-negative circulating cancer cells as prognostic markers for colorectal cancer recurrence.

Lieto E, Galizia G, Orditura M, Romano C, Zamboli A, Castellano P, Mabilia A, Auricchio A, DE Vita F, Gemei M.

Oncol Lett. 2015 Feb;9(2):542-550. Epub 2014 Dec 1.

46.

Modified versus standard D2 lymphadenectomy in total gastrectomy for nonjunctional gastric carcinoma with lymph node metastasis.

Galizia G, Lieto E, De Vita F, Castellano P, Ferraraccio F, Zamboli A, Mabilia A, Auricchio A, De Sena G, De Stefano L, Cardella F, Barbarisi A, Orditura M.

Surgery. 2015 Feb;157(2):285-96. doi: 10.1016/j.surg.2014.09.012. Epub 2014 Dec 19.

PMID:
25532433
47.

Clinical management of advanced gastric cancer: the role of new molecular drugs.

De Vita F, Di Martino N, Fabozzi A, Laterza MM, Ventriglia J, Savastano B, Petrillo A, Gambardella V, Sforza V, Marano L, Auricchio A, Galizia G, Ciardiello F, Orditura M.

World J Gastroenterol. 2014 Oct 28;20(40):14537-58. doi: 10.3748/wjg.v20.i40.14537. Review.

48.

Identification and treatment of older persons with sarcopenia.

Lauretani F, Bautmans I, De Vita F, Nardelli A, Ceda GP, Maggio M.

Aging Male. 2014 Dec;17(4):199-204. doi: 10.3109/13685538.2014.958457. Epub 2014 Sep 10.

PMID:
25207857
49.

Effects of transdermal testosterone treatment on inflammatory markers in elderly males.

Maggio M, Snyder PJ, De Vita F, Ceda GP, Milaneschi Y, Lauretani F, Luci M, Cattabiani C, Peachey H, Valenti G, Cappola AR, Longo DL, Ferrucci L.

Endocr Pract. 2014 Nov;20(11):1170-7. doi: 10.4158/EP13357.OR.

50.

Relationship between vitamin D and inflammatory markers in older individuals.

De Vita F, Lauretani F, Bauer J, Bautmans I, Shardell M, Cherubini A, Bondi G, Zuliani G, Bandinelli S, Pedrazzoni M, Dall'Aglio E, Ceda GP, Maggio M.

Age (Dordr). 2014;36(4):9694. doi: 10.1007/s11357-014-9694-4. Epub 2014 Aug 3.

Supplemental Content

Loading ...
Support Center